- Home
- UTMD vs VCRE Comparison
UTMD vs VCRE Comparison
Compare UTMD & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTMD | VCRE |
|---|---|---|
| Founded | 1978 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.3M | 271.7M |
| IPO Year | 1994 | 2026 |
Fundamental Metrics
Financial Performance| Metric | UTMD | VCRE |
|---|---|---|
| Price | $74.81 | $9.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.03 |
| AVG Volume (30 Days) | ★ 28.0K | 24.8K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $38,520,000.00 | N/A |
| Revenue This Year | N/A | $101.29 |
| Revenue Next Year | N/A | $481.15 |
| P/E Ratio | $45.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $53.66 | $7.88 |
| 52 Week High | $76.89 | $14.01 |
Technical Indicators
Market Signals| Indicator | UTMD | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.92 | 42.61 |
| Support Level | $73.22 | $8.79 |
| Resistance Level | $75.38 | $12.08 |
| Average True Range (ATR) | 0.83 | 0.83 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 33.78 | 33.50 |
Price Performance
Historical ComparisonAbout UTMD Utah Medical Products Inc.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.